All In Biotech

Drug Trial Radar · NCT06971198

Phase I Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of HSK39004 Dry Powder Inhalation

Last checked: Nov 20, 2026Latest source record: May 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

26

Actual

Start

Feb 10, 2025

Primary completion

Mar 28, 2025

Study completion May 6, 2025

Sponsor

Sponsor type
Industry
First posted
May 14, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

To evaluate the safety, tolerability and pharmacokinetic characteristics of HSK39004 dry powder inhalation in healthy subjects.

Conditions

  • Healthy Volunteers

Interventions

  • HSK39004Drug

    0.75\~4mg

  • PlaceboDrug

    0.75\~4mg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. adverse eventsTime frame: From the enrollment of the subjects to 72 hours after the last administration

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shandong Provincial Qianfoshan Hospital

    Jinan, Shandong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.